APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Myotonic Dystrophy Drug

Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.

Myotonic dystrophy affects more than 1 in 8,000 people worldwide. While myotonic dystrophy can occur at any age, onset is typically in the 20s and 30s. It is the most common form of muscular dystrophy that begins in adulthood.

Drugs that have been used to treat myotonia include sodium channel blockers such as procainamide, phenytoin and mexiletine, tricyclic antidepressant drugs such as clomipramine or imipramine, benzodiazepines, calcium antagonists, taurine and prednisone.

Selected research

Market Structure

Global Myotonic Dystrophy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174015360328 December 2025185 pages

Choose your research edition.

Industry ResearchMyotonic Dystrophy Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Myotonic Dystrophy Drug Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Myotonic Dystrophy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Myotonic Dystrophy Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Myotonic Dystrophy Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.

Myotonic dystrophy affects more than 1 in 8,000 people worldwide. While myotonic dystrophy can occur at any age, onset is typically in the 20s and 30s. It is the most common form of muscular dystrophy that begins in adulthood.

Drugs that have been used to treat myotonia include sodium channel blockers such as procainamide, phenytoin and mexiletine, tricyclic antidepressant drugs such as clomipramine or imipramine, benzodiazepines, calcium antagonists, taurine and prednisone.

Read the full market overview

The classification of Myotonic Dystrophy Drug includes Sodium Channel Blocker, Tricyclic Antidepressant and Other, and the sale proportion of Sodium Channel Blocker in 2019 is about 50%. Myotonic Dystrophy Drug is widely sold through Hospital Pharmacy, Retail Pharmacy, etc. The most proportion of Myotonic Dystrophy Drug sold through for Hospital Pharmacy, and the proportion in 2019 is nearly 45%. North America is the largest consumption place, with a consumption market share over 45% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 28%. Lupin, Teva, ANI Pharmaceuticals, Mylan, Novartis, etc. are the leaders of the industry, with totally about 60% market shares.

This report provides an overview of the global Myotonic Dystrophy Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Myotonic Dystrophy Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Myotonic Dystrophy Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Myotonic Dystrophy Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Myotonic Dystrophy Drug Segment by Company

Lupin

Teva

ANI Pharmaceuticals

Mylan

Novartis

Sun Pharma

Mallinckrodt

Myotonic Dystrophy Drug Segment by Type

Sodium Channel Blocker

Tricyclic Antidepressant

Other

Myotonic Dystrophy Drug Segment by Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Other

Myotonic Dystrophy Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Myotonic Dystrophy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Myotonic Dystrophy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Myotonic Dystrophy Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Myotonic Dystrophy Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Myotonic Dystrophy Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Myotonic Dystrophy Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Myotonic Dystrophy Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Myotonic Dystrophy Drug Industry Trends Table 2. Myotonic Dystrophy Drug Industry Drivers Table 3. Myotonic Dystrophy Drug Industry Opportunities and Challenges Table 4. Myotonic Dystrophy Drug Industry Restraints Table 5. Global Myotonic Dystrophy Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Myotonic Dystrophy Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Myotonic Dystrophy Drug Sales by Manufacturers (K Unit) & (2021-2026) Table 8. Global Myotonic Dystrophy Drug Sales Market Share by Manufacturers Table 9. Global Myotonic Dystrophy Drug Average Sales Price (USD$/Unit) of Manufacturers (2021-2026) Table 10. Global Myotonic Dystrophy Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Myotonic Dystrophy Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Myotonic Dystrophy Drug Manufacturers, Product Type & Application Table 13. Global Myotonic Dystrophy Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Myotonic Dystrophy Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Sodium Channel Blocker Table 17. Major Manufacturers of Tricyclic Antidepressant Table 18. Major Manufacturers of Other Table 19. Global Myotonic Dystrophy Drug Sales by Type 2021 VS 2025 VS 2032 (K Unit) Table 20. Global Myotonic Dystrophy Drug Sales by Type (2021-2026) & (K Unit) Table 21. Global Myotonic Dystrophy Drug Sales by Type (2027-2032) & (K Unit) Table 22. Global Myotonic Dystrophy Drug Sales Market Share by Type (2021-2026) Table 23. Global Myotonic Dystrophy Drug Sales Market Share by Type (2027-2032) Table 24. Global Myotonic Dystrophy Drug Revenue by Type 2021 VS 2025 VS 2032 (K Unit) Table 25. Global Myotonic Dystrophy Drug Revenue by Type (2021-2026) & (K Unit) Table 26. Global Myotonic Dystrophy Drug Revenue by Type (2027-2032) & (K Unit) Table 27. Global Myotonic Dystrophy Drug Revenue Market Share by Type (2021-2026) Table 28. Global Myotonic Dystrophy Drug Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Pharmacy Table 30. Major Manufacturers of Retail Pharmacy Table 31. Major Manufacturers of Other Table 32. Global Myotonic Dystrophy Drug Sales by Application 2021 VS 2025 VS 2032 (K Unit) Table 33. Global Myotonic Dystrophy Drug Sales by Application (2021-2026) & (K Unit) Table 34. Global Myotonic Dystrophy Drug Sales by Application (2027-2032) & (K Unit) Table 35. Global Myotonic Dystrophy Drug Sales Market Share by Application (2021-2026) Table 36. Global Myotonic Dystrophy Drug Sales Market Share by Application (2027-2032) Table 37. Global Myotonic Dystrophy Drug Revenue by Application 2021 VS 2025 VS 2032 (K Unit) Table 38. Global Myotonic Dystrophy Drug Revenue by Application (2021-2026) & (K Unit) Table 39. Global Myotonic Dystrophy Drug Revenue by Application (2027-2032) & (K Unit) Table 40. Global Myotonic Dystrophy Drug Revenue Market Share by Application (2021-2026) Table 41. Global Myotonic Dystrophy Drug Revenue Market Share by Application (2027-2032) Table 42. Global Myotonic Dystrophy Drug Sales by Region: 2021 VS 2025 VS 2032 (K Unit) Table 43. Global Myotonic Dystrophy Drug Sales by Region (2021-2026) & (K Unit) Table 44. Global Myotonic Dystrophy Drug Sales Market Share by Region (2021-2026) Table 45. Global Myotonic Dystrophy Drug Sales Forecasted by Region (2027-2032) & (K Unit) Table 46. Global Myotonic Dystrophy Drug Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Myotonic Dystrophy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Unit) Table 48. North America Myotonic Dystrophy Drug Sales by Country (2021-2026) & (K Unit) Table 49. North America Myotonic Dystrophy Drug Sales by Country (2027-2032) & (K Unit) Table 50. Europe Myotonic Dystrophy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Unit) Table 51. Europe Myotonic Dystrophy Drug Sales by Country (2021-2026) & (K Unit) Table 52. Europe Myotonic Dystrophy Drug Sales by Country (2027-2032) & (K Unit) Table 53. Asia Pacific Myotonic Dystrophy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Unit) Table 54. Asia Pacific Myotonic Dystrophy Drug Sales by Country (2021-2026) & (K Unit) Table 55. Asia Pacific Myotonic Dystrophy Drug Sales by Country (2027-2032) & (K Unit) Table 56. South America, Middle East and Africa Myotonic Dystrophy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Unit) Table 57. South America, Middle East and Africa Myotonic Dystrophy Drug Sales by Country (2021-2026) & (K Unit) Table 58. South America, Middle East and Africa Myotonic Dystrophy Drug Sales by Country (2027-2032) & (K Unit) Table 59. Global Myotonic Dystrophy Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Myotonic Dystrophy Drug Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Myotonic Dystrophy Drug Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Myotonic Dystrophy Drug Revenue Market Share by Region (2021-2026) Table 63. Global Myotonic Dystrophy Drug Revenue Market Share by Region (2027-2032) Table 64. Lupin Company Information Table 65. Lupin Business Overview Table 66. Lupin Myotonic Dystrophy Drug Sales (K Unit), Price (USD$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Lupin Myotonic Dystrophy Drug Product Portfolio Table 68. Lupin Recent Development Table 69. Teva Company Information Table 70. Teva Business Overview Table 71. Teva Myotonic Dystrophy Drug Sales (K Unit), Price (USD$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Teva Myotonic Dystrophy Drug Product Portfolio Table 73. Teva Recent Development Table 74. ANI Pharmaceuticals Company Information Table 75. ANI Pharmaceuticals Business Overview Table 76. ANI Pharmaceuticals Myotonic Dystrophy Drug Sales (K Unit), Price (USD$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. ANI Pharmaceuticals Myotonic Dystrophy Drug Product Portfolio Table 78. ANI Pharmaceuticals Recent Development Table 79. Mylan Company Information Table 80. Mylan Business Overview Table 81. Mylan Myotonic Dystrophy Drug Sales (K Unit), Price (USD$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Mylan Myotonic Dystrophy Drug Product Portfolio Table 83. Mylan Recent Development Table 84. Novartis Company Information Table 85. Novartis Business Overview Table 86. Novartis Myotonic Dystrophy Drug Sales (K Unit), Price (USD$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Novartis Myotonic Dystrophy Drug Product Portfolio Table 88. Novartis Recent Development Table 89. Sun Pharma Company Information Table 90. Sun Pharma Business Overview Table 91. Sun Pharma Myotonic Dystrophy Drug Sales (K Unit), Price (USD$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Sun Pharma Myotonic Dystrophy Drug Product Portfolio Table 93. Sun Pharma Recent Development Table 94. Mallinckrodt Company Information Table 95. Mallinckrodt Business Overview Table 96. Mallinckrodt Myotonic Dystrophy Drug Sales (K Unit), Price (USD$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Mallinckrodt Myotonic Dystrophy Drug Product Portfolio Table 98. Mallinckrodt Recent Development Table 99. Key Raw Materials Table 100. Raw Materials Key Suppliers Table 101. Myotonic Dystrophy Drug Distributors List Table 102. Myotonic Dystrophy Drug Customers List Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. Myotonic Dystrophy Drug Product Image Figure 2. Global Myotonic Dystrophy Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Myotonic Dystrophy Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Myotonic Dystrophy Drug Sales (2021-2032) & (K Unit) Figure 5. Global Myotonic Dystrophy Drug Average Price (USD$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Myotonic Dystrophy Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Sodium Channel Blocker Image Figure 9. Tricyclic Antidepressant Image Figure 10. Other Image Figure 11. Global Myotonic Dystrophy Drug Sales by Type (2021 VS 2025 VS 2032) & (K Unit) Figure 12. Global Myotonic Dystrophy Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Myotonic Dystrophy Drug Sales Market Share by Type (2021-2032) Figure 14. Global Myotonic Dystrophy Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Unit) Figure 15. Global Myotonic Dystrophy Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Myotonic Dystrophy Drug Revenue Market Share by Type (2021-2032) Figure 17. Hospital Pharmacy Image Figure 18. Retail Pharmacy Image Figure 19. Other Image Figure 20. Global Myotonic Dystrophy Drug Sales by Application (2021 VS 2025 VS 2032) & (K Unit) Figure 21. Global Myotonic Dystrophy Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Myotonic Dystrophy Drug Sales Market Share by Application (2021-2032) Figure 23. Global Myotonic Dystrophy Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Unit) Figure 24. Global Myotonic Dystrophy Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Myotonic Dystrophy Drug Revenue Market Share by Application (2021-2032) Figure 26. North America Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 27. North America Myotonic Dystrophy Drug Sales Market Share by Country (2021-2032) Figure 28. U.S. Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 29. Canada Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 30. Mexico Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 31. Europe Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 32. Europe Myotonic Dystrophy Drug Sales Market Share by Country (2021-2032) Figure 33. Germany Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 34. France Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 35. U.K. Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 36. Italy Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 37. Netherlands Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 38. Asia Pacific Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 39. Asia Pacific Myotonic Dystrophy Drug Sales Market Share by Country (2021-2032) Figure 40. China Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 41. Japan Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 42. South Korea Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 43. Southeast Asia Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 44. India Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 45. Australia Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 46. South America, Middle East and Africa Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 47. South America, Middle East and Africa Myotonic Dystrophy Drug Sales Market Share by Country (2021-2032) Figure 48. Brazil Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 49. South Africa Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 50. Saudi Arabia Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 51. Turkey Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 52. Argentina Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 53. UAE Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 54. Egypt Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 55. Chile Myotonic Dystrophy Drug Sales and Growth Rate (2021-2032) & (K Unit) Figure 56. Global Myotonic Dystrophy Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Myotonic Dystrophy Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Myotonic Dystrophy Drug Revenue (2021-2032) & (US$ Million) Figure 59. North America Myotonic Dystrophy Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Myotonic Dystrophy Drug Revenue (2021-2032) & (US$ Million) Figure 61. Europe Myotonic Dystrophy Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Myotonic Dystrophy Drug Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Myotonic Dystrophy Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Myotonic Dystrophy Drug Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Myotonic Dystrophy Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Myotonic Dystrophy Drug Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Myotonic Dystrophy Drug Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Sodium Channel Blocker
  • Tricyclic Antidepressant
  • Other
Applications
  • Hospital Pharmacy
  • Retail Pharmacy
  • Other
Companies covered
  • Lupin
  • Teva
  • ANI Pharmaceuticals
  • Mylan
  • Novartis
  • Sun Pharma
  • Mallinckrodt

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Myotonic Dystrophy Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Myotonic Dystrophy Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Myotonic Dystrophy Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Myotonic Dystrophy Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Myotonic Dystrophy Drug Market Dynamics
  1. 2.1 Myotonic Dystrophy Drug Industry Trends
  2. 2.2 Myotonic Dystrophy Drug Industry Drivers
  3. 2.3 Myotonic Dystrophy Drug Industry Opportunities and Challenges
  4. 2.4 Myotonic Dystrophy Drug Industry Restraints
3 Myotonic Dystrophy Drug Market by Manufacturers
  1. 3.1 Global Myotonic Dystrophy Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Myotonic Dystrophy Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Myotonic Dystrophy Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Myotonic Dystrophy Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Myotonic Dystrophy Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Myotonic Dystrophy Drug Manufacturers, Product Type & Application
  7. 3.7 Global Myotonic Dystrophy Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Myotonic Dystrophy Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Myotonic Dystrophy Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Myotonic Dystrophy Drug Tier 1, Tier 2, and Tier 3
4 Myotonic Dystrophy Drug Market by Type
  1. 4.1 Myotonic Dystrophy Drug Type Introduction
  2. 4.1.1 Sodium Channel Blocker
  3. 4.1.2 Tricyclic Antidepressant
  4. 4.1.3 Other
  5. 4.2 Global Myotonic Dystrophy Drug Sales by Type
  6. 4.2.1 Global Myotonic Dystrophy Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Myotonic Dystrophy Drug Sales by Type (2021-2032)
  8. 4.2.3 Global Myotonic Dystrophy Drug Sales Market Share by Type (2021-2032)
  9. 4.3 Global Myotonic Dystrophy Drug Revenue by Type
  10. 4.3.1 Global Myotonic Dystrophy Drug Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Myotonic Dystrophy Drug Revenue by Type (2021-2032)
  12. 4.3.3 Global Myotonic Dystrophy Drug Revenue Market Share by Type (2021-2032)
5 Myotonic Dystrophy Drug Market by Application
  1. 5.1 Myotonic Dystrophy Drug Application Introduction
  2. 5.1.1 Hospital Pharmacy
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Myotonic Dystrophy Drug Sales by Application
  6. 5.2.1 Global Myotonic Dystrophy Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Myotonic Dystrophy Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Myotonic Dystrophy Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Myotonic Dystrophy Drug Revenue by Application
  10. 5.3.1 Global Myotonic Dystrophy Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Myotonic Dystrophy Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Myotonic Dystrophy Drug Revenue Market Share by Application (2021-2032)
6 Global Myotonic Dystrophy Drug Sales by Region
  1. 6.1 Global Myotonic Dystrophy Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Myotonic Dystrophy Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Myotonic Dystrophy Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Myotonic Dystrophy Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Myotonic Dystrophy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Myotonic Dystrophy Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Myotonic Dystrophy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Myotonic Dystrophy Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Myotonic Dystrophy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Myotonic Dystrophy Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Myotonic Dystrophy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Myotonic Dystrophy Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Myotonic Dystrophy Drug Revenue by Region
  1. 7.1 Global Myotonic Dystrophy Drug Revenue by Region
  2. 7.1.1 Global Myotonic Dystrophy Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Myotonic Dystrophy Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Myotonic Dystrophy Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Myotonic Dystrophy Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Myotonic Dystrophy Drug Revenue (2021-2032)
  8. 7.2.2 North America Myotonic Dystrophy Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Myotonic Dystrophy Drug Revenue (2021-2032)
  11. 7.3.2 Europe Myotonic Dystrophy Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Myotonic Dystrophy Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Myotonic Dystrophy Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Myotonic Dystrophy Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Myotonic Dystrophy Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Lupin
  2. 8.1.1 Lupin Company Information
  3. 8.1.2 Lupin Business Overview
  4. 8.1.3 Lupin Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Lupin Myotonic Dystrophy Drug Product Portfolio
  6. 8.1.5 Lupin Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Myotonic Dystrophy Drug Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 ANI Pharmaceuticals
  14. 8.3.1 ANI Pharmaceuticals Company Information
  15. 8.3.2 ANI Pharmaceuticals Business Overview
  16. 8.3.3 ANI Pharmaceuticals Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 ANI Pharmaceuticals Myotonic Dystrophy Drug Product Portfolio
  18. 8.3.5 ANI Pharmaceuticals Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Myotonic Dystrophy Drug Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Myotonic Dystrophy Drug Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Sun Pharma
  32. 8.6.1 Sun Pharma Company Information
  33. 8.6.2 Sun Pharma Business Overview
  34. 8.6.3 Sun Pharma Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sun Pharma Myotonic Dystrophy Drug Product Portfolio
  36. 8.6.5 Sun Pharma Recent Developments
  37. 8.7 Mallinckrodt
  38. 8.7.1 Mallinckrodt Company Information
  39. 8.7.2 Mallinckrodt Business Overview
  40. 8.7.3 Mallinckrodt Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mallinckrodt Myotonic Dystrophy Drug Product Portfolio
  42. 8.7.5 Mallinckrodt Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Myotonic Dystrophy Drug Value Chain Analysis
  2. 9.1.1 Myotonic Dystrophy Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Myotonic Dystrophy Drug Production Mode & Process
  6. 9.2 Myotonic Dystrophy Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Myotonic Dystrophy Drug Distributors
  9. 9.2.3 Myotonic Dystrophy Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst